Tags

Type your tag names separated by a space and hit enter

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Zhonghua Zhong Liu Za Zhi. 2011 Jul; 33(7):540-3.ZZ

Abstract

OBJECTIVE

To investigate the clinical value of combination of human epididymis protein 4 (HE4), CA125 and the Risk of Ovarian Malignancy Algorithm (ROMA) in diagnosis of ovarian carcinoma.

METHODS

To detect the serum concentration of HE4 using ELISA and CA125 using ECL in patients of ovarian carcinoma group (n = 119), borderline ovarian tumor group (n = 36), benign ovarian neoplasm group (n = 96) and female healthy control group (n = 53). The ROMA based on the serum level of CA125, HE4 and a woman's menopausal status was used to calculate the predicted probability (PP) and diagnostic results of ovarian cancers.

RESULTS

The receiver operating characteristic (ROC) analysis showed the cut-off value was 67.3 pmol/L (the AUC was 0.906, the sensitivity was 80.7% and specificity was 94.6%). The serum levels of HE4 and CA125 in the ovarian carcinoma group were significantly higher than that in the borderline ovarian tumor group, benign ovarian neoplasm group and female healthy control group (P < 0.01). The serum levels of CA125 and HE4 showed statistically no significant difference between the borderline ovarian tumor group and benign ovarian neoplasm group (P > 0.05). The levels of HE4 and CA125 were reduced significantly in ovarian patients after surgery therapy (P < 0.01). The sensitivity and specificity of HE4 + CA125 combination was 92.7% and 72.5%. The ROMA that can classify patients into high and low risk groups was established as 9.3% in premenopausal and 27.3% in postmenopausal women.

CONCLUSIONS

HE4 is a helpful biomarker for ovarian carcinoma diagnosis. Biomarker combination of HE4 and CA125, and applying of the ROMA are helpful to improve the accuracy in diagnosis of ovarian cancers.

Authors+Show Affiliations

Clinical Laboratory, Chinese Academy of Medical Sciences, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

22093635

Citation

Wang, Min-jie, et al. "[Diagnostic Value of Combining Detection of Human Epididymis Protein 4 and CA125 in Patients With Malignant Ovarian Carcinoma]." Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology], vol. 33, no. 7, 2011, pp. 540-3.
Wang MJ, Qi J, Wang H, et al. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Zhonghua Zhong Liu Za Zhi. 2011;33(7):540-3.
Wang, M. J., Qi, J., Wang, H., Li, X. X., Wei, B. J., Fu, C., Gao, J., & Han, B. B. (2011). [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology], 33(7), 540-3.
Wang MJ, et al. [Diagnostic Value of Combining Detection of Human Epididymis Protein 4 and CA125 in Patients With Malignant Ovarian Carcinoma]. Zhonghua Zhong Liu Za Zhi. 2011;33(7):540-3. PubMed PMID: 22093635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. AU - Wang,Min-jie, AU - Qi,Jun, AU - Wang,Hai, AU - Li,Xue-xiang, AU - Wei,Bao-jun, AU - Fu,Chao, AU - Gao,Jia, AU - Han,Bin-Bin, PY - 2011/11/19/entrez PY - 2011/11/19/pubmed PY - 2012/6/15/medline SP - 540 EP - 3 JF - Zhonghua zhong liu za zhi [Chinese journal of oncology] JO - Zhonghua Zhong Liu Za Zhi VL - 33 IS - 7 N2 - OBJECTIVE: To investigate the clinical value of combination of human epididymis protein 4 (HE4), CA125 and the Risk of Ovarian Malignancy Algorithm (ROMA) in diagnosis of ovarian carcinoma. METHODS: To detect the serum concentration of HE4 using ELISA and CA125 using ECL in patients of ovarian carcinoma group (n = 119), borderline ovarian tumor group (n = 36), benign ovarian neoplasm group (n = 96) and female healthy control group (n = 53). The ROMA based on the serum level of CA125, HE4 and a woman's menopausal status was used to calculate the predicted probability (PP) and diagnostic results of ovarian cancers. RESULTS: The receiver operating characteristic (ROC) analysis showed the cut-off value was 67.3 pmol/L (the AUC was 0.906, the sensitivity was 80.7% and specificity was 94.6%). The serum levels of HE4 and CA125 in the ovarian carcinoma group were significantly higher than that in the borderline ovarian tumor group, benign ovarian neoplasm group and female healthy control group (P < 0.01). The serum levels of CA125 and HE4 showed statistically no significant difference between the borderline ovarian tumor group and benign ovarian neoplasm group (P > 0.05). The levels of HE4 and CA125 were reduced significantly in ovarian patients after surgery therapy (P < 0.01). The sensitivity and specificity of HE4 + CA125 combination was 92.7% and 72.5%. The ROMA that can classify patients into high and low risk groups was established as 9.3% in premenopausal and 27.3% in postmenopausal women. CONCLUSIONS: HE4 is a helpful biomarker for ovarian carcinoma diagnosis. Biomarker combination of HE4 and CA125, and applying of the ROMA are helpful to improve the accuracy in diagnosis of ovarian cancers. SN - 0253-3766 UR - https://www.unboundmedicine.com/medline/citation/22093635/[Diagnostic_value_of_combining_detection_of_human_epididymis_protein_4_and_CA125_in_patients_with_malignant_ovarian_carcinoma]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0253-3766&amp;year=2011&amp;vol=33&amp;issue=7&amp;fpage=540 DB - PRIME DP - Unbound Medicine ER -